Pesquisar Neste Blog

terça-feira, 18 de janeiro de 2011

UFRJ cria método para detecção de tuberculose

O Brasil é um dos 22 países do mundo que concentram 80% 
dos casos de tuberculose, de acordo com a OMS

Raio X mostra pulmão atacado por tuberculose
Raio X mostra pulmão atacado por tuberculose

Rio de Janeiro - Nona causa de ingresso hospitalar e quarta em mortalidade por enfermidades infecciosas, a tuberculose vem aumentando no País. Para melhorar o diagnóstico da doença, a Coppe em parceria com a Faculdade de Medicina da Universidade Federal do Rio de Janeiro (UFRJ) desenvolveu o sistema Neural TB para diagnóstico precoce e acompanhamento da doença.

O programa roda em um netbook e consiste em um questionário minucioso que, preenchido, dará ao profissional de saúde a informação sobre a probabilidade do paciente ter tuberculose - e orientações para acompanhá-lo. “Os métodos tradicionais de detecção ou são caros ou lentos.O projeto piloto tem apoio do Programa Nacional de Controle de Tuberculose do Ministério da Saúde e está sendo implantado em dez unidades de saúde do Rio e em outros cinco municípios.

A baciloscopia é rápida, mas só acerta 60% dos casos. Já a cultura do escarro, que tem acerto superior a 80%, leva 40 dias”, diz um dos responsáveis pelo sistema, José Manuel Seixas.

Segundo dados da Organização Mundial de Saúde (OMS), o Brasil é um dos 22 países do mundo que concentram 80% dos casos de tuberculose. As informações são do jornal O Estado de S. Paulo.

Cientistas descobrem 'interruptor' de célula imune a inflamação

Proteína age como 'chave mestra' para glóbulos brancos aumentarem ou diminuírem processo

LONDRES - Cientistas encontraram uma proteína que age como uma "chave mestra" para determinar se certos glóbulos brancos do sangue são capazes de aumentar ou diminuir uma inflamação, descoberta que pode ajudar na busca de novos medicamentos para a artrite reumatoide.

Muitos pacientes com a doença são tratados com uma classe de drogas conhecida como fator de necrose tumoral (TNF, na sigla em inglês), inibidores fabricados por laboratórios como Abbott, Merck & Co, Pfizer e Amgen.

Mas cerca de 30% dos portadores não respondem aos medicamentos anti-TNF. Por isso, segundo especialistas, há uma necessidade urgente de desenvolver opções de tratamento mais eficazes.

No estudo, os cientistas do Imperial College de Londres descobriram que a proteína IRF5 atua como um interruptor molecular que controla se determinados glóbulos brancos, conhecidos como macrófagos, vão promover ou inibir uma inflamação.

Em um relato publicado na revista científica Nature Immunology, no último domingo, os autores disseram que os resultados sugerem que bloquear a produção da IRF5 em macrófagos pode ser uma forma eficaz de tratar uma ampla gama de doenças autoimunes, como artrite reumatoide, doença inflamatória intestinal, lúpus e esclerose múltipla.

Os pesquisadores também sugerem que impulsionar os níveis de IRF5 pode ajudar a tratar pessoas cujo sistema imunológico esteja fraco, comprometido ou danificado. "Nossos resultados mostram que a IRF5 é a chave mestra de um conjunto importante de células do sistema imunológico, o que determina o perfil dos genes ativados nas células", afirma Irina Udalova, pesquisadora sênior do trabalho.

"Isso é realmente animador, porque significa que, se conseguimos projetar moléculas que interferem na função da IRF5, é possível conceber novos tratamentos anti-inflamatórios para uma ampla variedade de condições", acrescenta.

Os pesquisadores disseram que a IRF5 parece funcionar pela substituição de genes que estimulam a resposta inflamatória e pelo amortecimento dos que a inibem. A proteína pode fazer isso por meio da interação direta com o DNA, ou por meio da interação com outras proteínas que controlam quais genes serão ativados, explicaram os autores.

A equipe de Irina está estudando agora como a IRF5 trabalha no nível molecular e com quais outras proteínas interage, a fim de planejar maneiras de bloquear seus efeitos.

A artrite reumatoide é uma doença inflamatória crônica que atinge cerca de 1% da população mundial e ocorre quando o sistema imunológico ataca por engano as articulações de todo o corpo.

Além das articulações, a doença pode atingir a pele, o coração, os pulmões, os rins e os vasos sanguíneos. Muitos chegam a sofrer deformidades nas mãos e nos pés, prejudicando habilidades e movimentos. 

Aberrations in Adipose Tissue Could Increase Risk of Diabetes in Women With Polycystic Ovary Syndrome

ScienceDaily (Jan. 17, 2011) — A study from the University of Gothenburg, shows that women with polycystic ovary syndrome (PCOS) have aberrations in their adipose (fat) tissue. This discovery could provide answers as to why these women develop type 2 diabetes more readily, and shows that it is important for their health that women with PCOS do not put on weight.

"We already know that women with PCOS often have insulin resistance, in other words the body's cells are less sensitive to insulin, and are at greater risk of developing type 2 diabetes," says Louise Mannerås-Holm, a researcher at the Department of Physiology at the Sahlgrenska Academy's Institute of Neuroscience and Physiology. "High levels of testosterone in the blood of these women are thought to be one of the main reasons for this." But the current study, published in The Journal of Clinical Endocrinology and Metabolism, shows that aberrations in adipose tissue could be more significant in this respect. Around half of all women with PCOS are overweight or obese and it is widely believed that the excess fat is stored mainly around the middle.

The study therefore pair-matched 31 women with PCOS and 31 women without the syndrome, but of the same age and BMI. Ages ranged from 21 to 37, and BMI from underweight to extremely obese. "The comparison between the groups shows that women with PCOS do not have an abnormally large amount of fat around the middle, but that they do have large fat cells and altered adipose tissue function," says Mannerås-Holm.

In women with PCOS, adipose tissue produces less of the "good" hormone adiponectin which increases the body's sensitivity to insulin. Furthermore, activity of the enzyme lipoprotein lipase is low, which can affect the metabolism of fat in the body.

A total of 74 women with PCOS took part in the study, which also shows that the aberrations in adipose tissue in PCOS could play a key role in increasing these women's risk of developing type 2 diabetes. The factors linked most strongly with insulin resistance were the size of the fat cells, the quantity of adiponectin in the blood and waist size. However, testosterone levels did not play a significant role in this analysis.

"We don't entirely understand the mechanism behind the large fat cells' unfavourable effects, but the results show that it is particularly important for the health of women with PCOS that they don't put on weight," says Mannerås-Holm.

Polycystic Ovary Syndrome (PCOS)

PCOS is the most common hormonal disorder in women of fertile age. Characterised by insulin resistance and high levels of testosterone, PCOS affects 5-10% of fertile women.

The most common symptoms are irregular or disrupted menstruation, problem hair growth, acne and excess weight. In the long term women with PCOS are at greater risk of developing type 2 diabetes, and probably cardiovascular disease too. Extensive research is under way to increase our knowledge of the underlying factors.

Docent Malin Lönn at the Sahlgrenska Academy supervised the study of adipose tissue in PCOS, which was part of an extensive investigation into these women's physical and mental health led by docent Elisabet Stener-Victorin at the Sahlgrenska Academy.

New Technique to See Neurons of the Deep Brain for Months at a Time

ScienceDaily (Jan. 17, 2011) — Travel just one millimeter inside the brain and you'll be stepping into the dark. Standard light microscopes don't allow researchers to look into the interior of the living brain, where memories are formed and diseases such as dementia and cancer can take their toll.

Mark Schnitzer, associate professor of biology and applied physics, right, and Juergen Jung, operations director of the Schnitzer lab, in front of the microscope setup used to image the deep brain. (Credit: L.A. Cicero, Stanford University News Service)
But Stanford scientists have devised a new method that not only lets them peer deep inside the brain to examine its neurons but also allows them to continue monitoring for months.

The technique promises to improve understanding of both the normal biology and diseased states of this hidden tissue.

Other recent advances in micro-optics had enabled scientists to take a peek at cells of the deep brain, but their observations captured only a momentary snapshot of the microscopic changes that occur over months and years with aging and illness.

The Stanford development appears online Jan. 16 in the journal Nature Medicine. It also will appear in the February 2011 print edition.

Scientists study many diseases of the deep brain using mouse models, mice that have been bred or genetically engineered to have diseases similar to human afflictions.

"Researchers will now be able to study mouse models in these deep areas in a way that wasn't available before," said senior author Mark Schnitzer, associate professor of biology and of applied physics.

Because light microscopy can only penetrate the outermost layer of tissues, any region of the brain deeper than 700 microns or so (about 1/32 of an inch) cannot be reached by traditional microscopy techniques. Recent advances in micro-optics had allowed scientists to briefly peer deeper into living tissues, but it was nearly impossible to return to the same location of the brain and it was very likely that the tissue of interest would become damaged or infected.

With the new method, "Imaging is possible over a very long time without damaging the region of interest," said Juergen Jung, operations manager of the Schnitzer lab. Tiny glass tubes, about half the width of a grain of rice, are carefully placed in the deep brain of an anaesthetized mouse. Once the tubes are in place, the brain is not exposed to the outside environment, thus preventing infection. When researchers want to examine the cells and their interactions at this site, they insert a tiny optical instrument called a microendoscope inside the glass guide tube. The guide tubes have glass windows at the ends through which scientists can examine the interior of the brain.

"It's a bit like looking through a porthole in a submarine," said Schnitzer.

The guide tubes allow researchers to return to exactly the same location of the deep brain repeatedly over weeks or months. While techniques like MRI scans could examine the deep brain, "they couldn't look at individual cells on a microscopic scale," said Schnitzer. Now, the delicate branches of neurons can be monitored during prolonged experiments.

To test the use of the technique for investigating brain disease, the researchers looked at a mouse model of glioma, a deadly form of brain cancer. They saw hallmarks of glioma growth in the deep brain that were previously known in tumors described as surficial (on or near the surface).

The severity of glioma tumors depends on their location. "The most aggressive brain tumors arise deep and not superficially," said Lawrence Recht, professor of neurology and neurological sciences. Why the position of glioma tumors affects their growth rate isn't understood, but this method would be a way to explore that question, Recht said.

In addition to continuing their studies of brain disease and the neuroscience of memory, the researchers hope to teach other researchers how to perform the technique.

The first three authors of the paper (all of whom contributed equally to the study) are Robert Barretto, a former doctoral student in biophysics and now a postdoctoral researcher at Columbia University Medical Center; Tony Ko, a former postdoctoral researcher in the Department of Biology; and Jung. Also contributing to the work -- and listed as authors -- are Tammy Wang, a former undergraduate in biomedical engineering; George Capps and Allison Waters, both former undergraduates in biology; and Yaniv Ziv and Alessio Attardo, both postdoctoral researchers in biology

Silicon Microdevices Show Promise for Detecting Metastatic Breast Cancer Cells

ScienceDaily (Jan. 17, 2011) — Research by engineers and cancer biologists at Virginia Tech indicate that using specific silicon microdevices might provide a new way to screen breast cancer cells' ability to metastasize.

The Virginia Tech researchers are: Masoud Agah, director of Virginia Tech's Microelectromechanical Systems Laboratory (MEMS) Laboratory in the Bradley Department of Electrical and Computer Engineering; Jeannine Strobl, a research professor in the Bradley Department of Electrical and Computer Engineering; Mehdi Nikkhah of mechanical engineering; and Raffaella DeVita of engineering science and mechanics and the director of the soft biological systems laboratory. Nikkhah was Virginia Tech's Outstanding Doctoral Student in the College of Engineering for 2009.

Their work appeared in two journal articles they authored in 2010 issues of Biomaterials.

Cell cytoskeleton refers to the cell's shape and its mechanical properties, Agah explained. "Any change in the cytoskeletal structure can affect the interaction of cells with their surrounding microenvironments. Biological events in normal cells such as embryonic development, tissue growth and repair, and immune responses, as well as cancer cell motility and invasiveness are dependent upon cytoskeletal reorganization," the electrical engineer added.

Understanding how the cell interacts with the contents of its surrounding environment inside the human body, including the introduction of a drug, is a fundamental biological question. The answers have implications in cancer diagnosis and therapy, as well as tissue engineering, Agah said.

In previous experimentation by others in the field, researchers have exposed cells to mechanical, chemical and three-dimensional topographical stimuli. They recorded the cells' various responses in terms of migration, growth, and ability to adhere. Also, in the past, researchers have created substrates of precise micro- and nano-topographical and chemical patterns to mimic in vivo microenvironments for biological and medical applications.

What distinguishes the work of Agah, a National Science Foundation (NSF) CAREER Award recipient, and his colleagues, is they developed a specific three-dimensional silicon microstructure for their work. Due to its curved isotropic surfaces, they were able to characterize and compare the growth and adhesion behavior of normal fibroblast and metastatic human breast cancer cells, they reported inBiomaterials.

"In invasive breast carcinoma, tumor cells will fill a milk duct, and the basement membrane," they wrote. This action allows the carcinoma cells and the fibroblast cells of the breast tissue to be in close proximity, constituting "a critical pathobiological transition that leads to the progression of the disease," Strobl said.

Using their uniquely designed three-dimensional silicon microstructure, they were able to incorporate three key cellular components found in any breast tumor microenvironment. Additionally, they were able to determine the detailed interaction of the cells within this environment, including the normal breast cells, the metastatic breast cancer cells, and the fibroblast cells.

Their understanding of the behavior of the cells within the microstructures is what leads them to believe their research could "provide important diagnostic and prognostic markers unique to the tumor, which could ultimately be used to develop new tools for the detection and treatment of cancer."

Following their initial findings, Strobl, Nikkhah and Agah identified a unique application of the experimental anti-cancer drug SAHA in their studies with the silicon microstructure. SAHA, also known as Vorinostat, is the first drug of its type to receive Food and Drug Administration approval for clinical use in cancer treatment.

Unlike many of the conventional cytotoxic chemotherapy agents that target DNA to kill cancer cells, SAHA's unique properties include its ability to inhibit a family of enzymes referred to medically as "histone deacetylases." These enzymes are known to "increase levels of acetylation of many proteins, including beta-actin, alpha-, and beta-tubulin, and additional actin binding proteins comprising the cytoskeleton.

"The role of drugs such as SAHA in the control of cancer cell metastasis is only beginning to be understood," explained Strobl, "however our work shows that SAHA elicits a very characteristic cytoskeletal alteration specifically in metastatic breast cells that provides a handle for predicting which breast cells in a cell mixture might have the ability to metastasize."

Cell motility is "one hallmark of metastatic cancer cells involving the coordinated actions of actin and other cytoskeleton proteins," Agah explained. When metastatic disease develops, it is usually fatal.

They found SAHA caused cancer cells to stretch and attach to the microstructures through actin-rich cell extensions. By contrast, control cells conformed to the microstructures. This result allowed them to "conclude that isotropically etched silicon microstructures comprise microenvironments that discriminate metastatic mammary cancer cells in which cytoskeletal elements reorganized in response to the anti-cancer agent SAHA."

The Virginia Tech work in this area "is the first to address the use of microdevices to study this emerging class of anti-cancer agents," Agah said.